New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease.

Abstract : UNLABELLED: ABSTRACT: BACKGROUND: Amyloid precursor protein (APP), a key molecule in Alzheimer's disease (AD), is metabolized in two alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal fluid (CSF) is considered to be a biomarker of AD, whereas the level of sAPPα in CSF as a biomarker has not been clearly established. sAPPα has neurotrophic and neuroprotective properties. Stimulating its formation and secretion is a promising therapeutic target in AD research. To this end, very sensitive tests for preclinical and clinical research are required. METHODS: The tests are based on homogenous time-resolved fluorescence and require no washing steps. RESULTS: We describe two new rapid and sensitive tests for quantifying mouse and human sAPPα. These 20 μl-volume tests quantify the levels of: i) endogenous mouse sAPPα in the conditioned medium of mouse neuron primary cultures, as well as in the CSF of wild-type mice, ii) human sAPPα in the CSF of AD mouse models, and iii) human sAPPα in the CSF of AD and non-AD patients. These tests require only 5 μl of conditioned medium from 5 × 104 mouse primary neurons, 1 μl of CSF from wild-type and transgenic mice, and 0.5 μl of human CSF. CONCLUSIONS: The high sensitivity of the mouse sAPPα test will allow high-throughput investigations of molecules capable of increasing the secretion of endogenous sAPPα in primary neurons, as well as the in vivo validation of molecules of interest through the quantification of sAPPα in the CSF of treated wild-type mice. Active molecules could then be tested in the AD mouse models by quantifying human sAPPα in the CSF through the progression of the disease. Finally, the human sAPPα test could strengthen the biological diagnosis of AD in large clinical investigations. Taken together, these new tests have a wide field of applications in preclinical and clinical studies.
Type de document :
Article dans une revue
BMC Neuroscience, BioMed Central, 2012, 13 (1), pp.84. 〈10.1186/1471-2202-13-84〉
Liste complète des métadonnées

Littérature citée [43 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00723764
Contributeur : Ed. Bmc <>
Soumis le : lundi 13 août 2012 - 17:01:30
Dernière modification le : lundi 18 décembre 2017 - 10:02:01
Document(s) archivé(s) le : mercredi 14 novembre 2012 - 02:35:28

Fichiers

Identifiants

Collections

Citation

Christiane Rose, Katell Peoc'H, Stéphanie Chasseigneaux, Claire Paquet, Julien Dumurgier, et al.. New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease.. BMC Neuroscience, BioMed Central, 2012, 13 (1), pp.84. 〈10.1186/1471-2202-13-84〉. 〈inserm-00723764〉

Partager

Métriques

Consultations de la notice

242

Téléchargements de fichiers

222